论文部分内容阅读
目的观察早期和临床期糖尿病肾脏病血清丙酮醛(MGO)、血清脂联素(APN)、血清血管内皮生长因子(VEGF)的差异及演变特点。方法收集2012~2014年就诊于北京中医药大学东直门医院及东区、北京中医药大学第三附属医院,临床诊断为糖尿病肾脏病患者,其中早期糖尿病肾脏病组(早期组)152例,临床期糖尿病肾脏病组(临床期组)56例,2组均接受规范合理的降糖、降压等基础和药物治疗并控制在较合理范围。基线及6个月后分别收集血清并保存,运用酶联免疫吸附法(ELISA)法检测血清MGO、APN、VEGF水平,并观察2组间基线水平和6个月后3指标差异,及组内指标6个月内变化情况。结果与早期组相比,临床期组基线水平及6个月后血清MGO、VEGF水平均升高(P<0.05),血清APN无差异;早期组6个月内APN水平有升高(P<0.05),MGO、VEGF无显著变化;临床期组6个月内血清MGO、APN、VEGF均无显著变化(P>0.05)。结论早期糖尿病肾脏病患者血清MGO、VEGF水平升高可一定程度上提示患者病情有向前进展可能,可为早期糖尿病肾脏病患者病情监测提供参考。
Objective To observe the differences and evolvement characteristics of serum pyruvate (MGO), serum adiponectin (APN) and serum vascular endothelial growth factor (VEGF) in early and clinical diabetic nephropathy. Methods A total of 152 patients with early stage diabetic nephropathy (early stage) were enrolled in this study. They were from Dongzhimen Hospital of Beijing University of Chinese Medicine and the Dongzu Hospital of Beijing University of Chinese Medicine and the Third Affiliated Hospital of Beijing University of Chinese Medicine from 2012 to 2014. Clinical data of patients with diabetic nephropathy Nephrotic group (clinical stage group) 56 cases, 2 groups received standard and reasonable hypoglycemic, antihypertensive and other basic and drug treatment and control in a more reasonable range. Serum levels of MGO, APN and VEGF were detected by enzyme linked immunosorbent assay (ELISA) at baseline and 6 months after treatment. The baseline levels and the differences of 3 indexes after 6 months were observed. Indicators changes within 6 months. Results Compared with the early group, the serum level of MGO and VEGF in the clinical group were significantly increased (P <0.05) and the serum APN was no difference in the baseline group and the APO level in the 6-month early group (P < 0.05). There was no significant change in MGO and VEGF. Serum MGO, APN and VEGF in clinical group had no significant change within 6 months (P> 0.05). Conclusion The elevated serum levels of MGO and VEGF in patients with early diabetic nephropathy may be somehow prompted the patient’s progress may be forward, which may provide a reference for monitoring the disease in patients with early diabetic nephropathy.